FDA clears hands-free robotic system for CT exams

XACT Robotics, a radiology technology company with offices in Hingham, Massachusetts, and Israel, received FDA clearance for the use of its hands-free robotic system during CT examinations.

This is the first hands-free robotic solution of its kind, according to the company, providing users with both imaging-based navigation and the ability to insert and steer “various instruments to a desired target across an array of clinical applications and indications.”

“We are committed to redefining the way the entire medical community utilizes robotics, beginning with interventional radiologists,” Harel Gadot, founder, executive chairman and president of XACT Robotics, said in a prepared statement. “Being the first to introduce a hands-free robotic system, we have the potential to provide significant clinical, technical and economic value while democratizing interventional procedures. Our system’s small footprint and high mobility design will enable care providers to treat a broad range of patient care needs in various clinical sites of service.”  

“The XACT Robotic System provides a unique platform to the interventional radiology community which can help improve the delivery and quality of care for the patients we serve,” Nahum S. Goldberg, MD, director of the Applied Radiology Research Lab at Hadassah Hebrew University Medical Center in Israel, said in the same statement. “Based on our experience with this unique robotic technology, we can reach very small targets with unprecedented accuracy. Furthermore, this system holds much promise for enabling more efficient use of time and hospital resources.”

Goldberg has spent significant time with the solution, even leading a multi-site study into its effectiveness.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.